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Abstract
Background: Prostate-specific membrane antigen (PSMA) is frequently overexpressed and upregulated in prostate
cancer. To date, various 18F- and 68Ga-labeled urea-based radiotracers for PET imaging of PSMA have been
developed and entered clinical trials. Here, we describe an automated synthesis of [18F]DCFPyL via direct
radiofluorination and validation in preclinical models of prostate cancer.
Methods: [18F]DCFPyL was synthesized via direct nucleophilic heteroaromatic substitution reaction in a single
reactor TRACERlab FXFN automated synthesis unit. Radiopharmacological evaluation of [
18F]DCFPyL involved
internalization experiments, dynamic PET imaging in LNCaP (PSMA+) and PC3 (PSMA−) tumor-bearing BALB/c
nude mice, biodistribution studies, and metabolic profiling. In addition, reversible two-tissue compartmental
model analysis was used to quantify pharmacokinetics of [18F]DCFPyL in LNCaP and PC3 tumor models.
Results: Automated radiosynthesis afforded radiotracer [18F]DCFPyL in decay-corrected radiochemical yields of
23 ± 5 % (n = 10) within 55 min, including HPLC purification. Dynamic PET analysis revealed rapid and high
uptake of radioactivity (SUV5min 0.95) in LNCaP tumors which increased over time (SUV60min 1.1). Radioactivity
uptake in LNCaP tumors was blocked in the presence of nonradioactive DCFPyL (SUV60min 0.22). The muscle as
reference tissue showed rapid and continuous clearance over time (SUV60min 0.06). Fast blood clearance of
radioactivity resulted in tumor-blood ratios of 1.0 after 10 min and 8.3 after 60 min. PC3 tumors also showed
continuous clearance of radioactivity over time (SUV60min 0.11). Kinetic analysis of PET data revealed the two-tissue
compartmental model as best fit with K1 = 0.12, k2 = 0.18, k3 = 0.08, and k4 = 0.004 min
−1, confirming molecular trapping
of [18F]DCFPyL in PSMA+ LNCaP cells.
Conclusions: [18F]DCFPyL can be prepared for clinical applications simply and in good radiochemical yields via a direct
radiofluorination synthesis route in a single reactor automated synthesis unit. Radiopharmacological evaluation of
[18F]DCFPyL confirmed high PSMA-mediated tumor uptake combined with superior clearance parameters.
Compartmental model analysis points to a two-step molecular trapping mechanism based on PSMA binding
and subsequent internalization leading to retention of radioactivity in PSMA+ LNCaP tumors.
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Background
Prostate cancer is among the most common malignancy
in men in Western countries and accounts for the fifth
leading cause of cancer-related death in men [1]. This
situation clearly underscores prostate cancer as a highly
frequent but still unmet medical challenge which con-
tinues to be the target of a significant proportion of
current clinical research, including to a large extent the
development of novel radiotracers for positron emission
tomography (PET) imaging of prostate cancer [2, 3].
PET imaging of prostate cancer was successfully demon-
strated with various 11C- and 18F-labeled choline analogs,
as well as 11C-acetate for imaging cell membrane and fatty
acid metabolism in prostate cancer [4, 5]. PET imaging of
prostate cancer with [18F]FDG, the most widely used ra-
diopharmaceutical for cancer imaging, gave mixed results.
[18F]FDG-PET is not useful in the detection of primary
organ-confined prostate cancer and local recurrences
after radical prostatectomy, as well as in differentiating
between post-operative scar and local recurrence. How-
ever, [18F]FDG uptake in prostate cancer was reported
to correlate with prostate-specific antigen (PSA) level
as a biomarker to measure tumor aggressiveness [6].
[18F]FDG-PET was also used to monitor therapeutic re-
sponse of patients with androgen-independent disease [7, 8].
The aforementioned limitations of [18F]FDG-PET in
connection with the importance of prostate cancer as a
significant unmet clinical need drive current develop-
ments towards targeted molecular imaging of prostate
cancer. One prominent class of agents that exemplifies
the outcome of this effort includes radiotracers targeting
the trans-membrane protein, prostate-specific membrane
antigen (PSMA) [9]. PSMA is a highly promising biomarker
for targeted prostate cancer imaging due to its elevated ex-
pression and up-regulation in poorly differentiated, meta-
static, and androgen-independent carcinomas.
PSMA is a particularly important molecular target in
prostate cancer patients with negative bone scans who
are at high risk for metastatic disease. Moreover, PSMA
is an ideal target for developing small-molecule radio-
pharmaceuticals which typically show fast blood clear-
ance and low background activity [9]. Over the past
decade, several urea-based and phosphoramidate pepti-
domimetic inhibitors of PSMA have been developed
and labeled with positron emitters such as 11C, 18F,
68Ga, 64Cu, 124I, and 86Y [9]. Among these small-molecule
PSMA-imaging agents, especially 68Ga-labeled compounds
have been introduced into clinical applications for PSMA
imaging in prostate cancer patients [10, 11]. Although
68Ga-labeled small-molecule PSMA inhibitors exhibit favor-
able clinical imaging properties, improved lesion detection
could be further enhanced using 18F due to its lower posi-
tron energy and longer half-life, or improved retention due
to the chemical nature of existing agents. This was recently
demonstrated by the first comparative clinical study of
18F-labeled PSMA inhibitor [18F]DCFPyL with [68Ga]Ga-
PSMA-HBED-CC [12].
Another challenge associated with 68Ga-labeled radio-
pharmaceuticals for clinical imaging is the less than opti-
mal availability of 68Ga generators, especially with respect
to their regulatory status in North America. Given the
small quantity of 68Ga eluted from 68Ga generators (typic-
ally up to 1850 MBq), producing more than 1–3 doses per
production batch is also challenging, which increases pro-
duction costs.
However, despite the inherent advantages of 18F like
the favorable physical half-life of 109.8 min and the con-
venient availability as cyclotron-produced [18F]fluoride
at high specific activity, the production of 18F-labeled
small-molecule PSMA inhibitors is complicated and
often low yielding [13–20].
In all cases, radiosyntheses were accomplished via
challenging prosthetic group-based multi-step synthesis
routes or aluminum-[18F]fluoride acceptor chemistry.
Prosthetic group-based radiosyntheses included prepar-
ation of 2,3,5,6-tetrafluorophenyl-6-[18F]fluoronicotinate
([18F]FPy-TFP), 4-[18F]fluorobenzyl bromide [18F]FBB)
and N-succinimidyl-4-[18F]fluorobenzoate ([18F]SFB) as
18F-containing building blocks followed by bioconjuga-
tion chemistry through N-acylation and S-alkylation re-
actions, respectively (Fig. 1).
First clinical results demonstrated that [18F]DCFPyL is
a promising radiotracer for PET imaging of prostate can-
cer and clear cell renal cell carcinoma. The promising
clinical results stimulated efforts for the development of
automated radiosyntheses based on more desirable dir-
ect radiofluorination reactions to simplify preparation
and therefore to improve availability of [18F]DCFPyL as
a radiopharmaceutical for PET imaging of PSMA.
Here, we describe a novel automated radiosynthesis of
[18F]DCFPyL via a direct radiofluorination procedure in
an automated synthesis unit (ASU) suitable for use under
good manufacturing practice (GMP) guidelines. We also
present preclinical data on the radiopharmacological pro-
file of [18F]DCFPyL in PSMA+ LNCaP and PSMA− PC3
tumor xenografts which further confirmed the quality of
the resulting radiotracer for targeted molecular imaging of
PSMA in prostate cancer.
Methods
All chemicals, reagents, and solvents for the synthesis
and analysis were analytical grade. The amino acid pre-
cursors H-Glu(OtBu)-OtBu.HCl and H-Lys(Z)-OtBu.HCl
were purchased from EMD Millipore. The Bu4N
+-HCO3
−
solution and Chromafix (30-PS-HCO3, Macherey-Nagel)
cartridges were purchased from ABX. All other chemicals
and solvents were purchased from Sigma-Aldrich. All
solvents were dried and/or distilled prior to utilization.
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1H-NMR and 13C-NMR spectra were recorded on an
Agilent/Varian Inova two-channel 400-MHz spectrom-
eter, an Agilent/Varian Inova four-channel 500-MHz
spectrometer, and an Agilent/Varian VNMRS three-
channel 600-MHz spectrometer. Chemical shifts are
given in parts per million (ppm) referenced to internal
standards (s = singlet, bs = broad singlet, d = doublet,
dd = doublet of doublet, ddd = doublet of doublet of
doublet, t = triplet, M =multiplet, m =massif ). Mass spec-
tra were recorded using a Micromass ZABSpec Hybrid
Sector-TOF by positive mode electrospray ionization.
High resolution mass spectra (HRMS) were carried out on
an Agilent Technologies 6220 oaTOF. Crude reaction
mixtures were analyzed by TLC and HPLC. Thin-layer
chromatography (TLC) was monitored using HF254 silica
gel. HPLC analyses were performed on a semi-preparative
Luna C18 column (100 Å, 10 μm, 250 × 10 mm) or Jupiter
C12 (100 Å, 10 μm, 250 × 10 mm).
Both columns were connected to their corresponding
guard columns (Phenomenex Nucleosil LUNA (II) RP
C18 pre-column (5 μm, 50 × 10 mm) and Jupiter C12
pre-column (5 μm, 50 × 10 mm)). UV detection was per-
formed at 210 and 254 nm. Radioactivity detection was
achieved using a well-scintillation NaI (Tl) detector.
[18F]Fluoride was produced by the 18O(p,n)18F nuclear
reaction through proton irradiation of enriched (98 %)
18O water (3.0 mL, ROTEM, Germany) using a TR19/9





One hundred fifty milligrams (0.507 μmol) of Glu(OtBu)-
OtBu·HCl 1 was dissolved in 2 mL of freshly distilled
CH3CN. Seventy microliters of Et3N (0.507 μmol) and
142 mg (0.554 μmol) of N,N′-disuccinimidyl carbonate was
added to the solution. The reaction was stirred at 25 °C for
12 h and concentrated under reduced pressure. After re-
solubilization in 5 mL of EtOAc and successive washing
with 10 mL of 10 % citric acid and 10 mL of brine, the or-
ganic layer was dried over Na2SO4 and concentrated under
reduced pressure to afford 197 mg of a pale yellow powder.
This unpurified powder contained 90 % of desired com-
pound 2 (yield 78 %). TLC: (EtOAc/hexane, 3/1): Rf = 0.7.
1H-NMR (400 MHz, CDCl3) δ: 1.46 (s, 9H), 1.50 (s, 9H),
1.94–2.14 (m, 1H), 2.10–2.21 (m, 1H), 2.24–2.44 (m, 2H),
2.83 (s, 4H), 4.23 (dt, 1H, J = 5.1 Hz, J = 7.7 Hz), 6.19 (d,
1H, J = 7.7 Hz). 13C-NMR (100.5 MHz, CDCl3) δ: 25.47,
27.59, 27.97, 28.00, 31.15, 54.78, 80.95, 83.09, 151.06,
169.60, 169.76, 171.95.
Fig. 1 Structure of 18F-labeled small-molecule PSMA inhibitors




Compounds 4 and 5 and DCFPyL were previously syn-
thesized [15, 16]. Herein, we describe an improved
methodology. The yellow powder containing 90 % of
compound 2 (197 mg, 90 % purity) was dissolved
without further purification in 3 mL of CH2Cl2 con-
taining 100 μL of Et3N and 187 mg (501 μmol) of μs-
benzyloxycarbonyl-L-lysine tert.-butyl ester hydrochloride
(H-Lys(Z)-OtBu.HCl) 3. The reaction mixture was stirred
for 12 h at 25 °C, and progress of the reaction was moni-
tored by TLC (CH2Cl2/MeOH 95/5). Upon completion,
the reaction mixture was concentrated under reduced
pressure and the residue was purified by column chroma-
tography (CH2Cl2/MeOH 95/5) to afford 252 mg (92 %)
of desired compound 4 as a clear gel. TLC: (CH2Cl2/
MeOH 95/5): Rf = 0.2.
1H-NMR (600 MHz, CDCl3) δ:
1.16–1.24 (m, 1H), 1.24–1.30 (m, 1H), 1.35 (s, 9H), 1.37
(s, 9H), 1.38 (s, 9H), 1.39–1.47 (m, 2H), 1.48–1.56 (m,
1H), 1.61–1.69 (m, 1H), 1.69–1.77 (m, 1H), 1.93–2.01
(m, 1H), 2.13–2.25 (m, 2H), 3.02–3.15 (m, 2H), 4.22–4.28
(m, 1H), 4.28–4.33 (m, 1H), 4.99 (d, 1H, J = 12.5 Hz), 5.05
(d, 1H, J = 12.5 Hz), 5.37 (d, 1H, J = 8 Hz), 5.44 (s, 1H),
5.45 (d, 1H, J = 8.1 Hz), 7.20–7.24 (m, 1H), 7.24–7.30 (m,
4H). 13C-NMR (150.9 MHz, CDCl3) δ: 21.36, 26.98, 27.00,
27.05, 27.32, 28.33, 30.56, 31.61, 39.69, 51.84, 52.25, 65.46,
79.44, 80.58, 81.14, 126.93, 127.03, 127.43, 135.76, 155.66,
156.10, 171.33, 171.57, 171.89. m/z (ESI) C32H51N3O9
([M +H+]) calcd. 622.4, found 622.4.
(S)-2-[3-((S)-5-Amino-1-tert.-
butoxycarbonylpentyl)ureido]pentanedioic acid di-tert.-
butyl ester 5 [15, 16]
A solution of compound 4 (220 mg, 0.354 μmol) in
3 mL of MeOH was stirred with 10 mg of Pd/C under
H2 atmosphere for 12 h. The reaction was filtered
through celite and concentration under reduced pressure
afforded 164 mg (95 %) of compound 5 as a clear gel.
1H-NMR (600 MHz, CD3OD) δ: 1.45–1.47 (m,1H), 1.47
(s, 9H), 1.47–1.49 (m, 1H) 1.49 (s, 9H) 1.50 (s, 9H),
1.57–1.70 (m, 3H), 1.78–1.86 (m, 2H), 2.04–2.10 (m,
1H), 2.28–2.40 (m, 2H), 2.79–2.88 (m, 2H), 4.18 (dd, 1H,
J = 5.1 Hz, J = 9.0. Hz), 4.22 (dd, 1H, J = 5.0 Hz, J =






In a flame-dried flask, HBTU (156 mg, 410 μmol),
DIPEA (72 μL, 410 μmol), and 6-fluoronicotinic acid 6
(58 mg, 410 μmol) were added to a solution of 100 mg
(0.205 μmol) of compound 5 in 4 mL of distilled CH2Cl2.
The reaction was stirred at 25 °C for 3 h under nitrogen,
and progress of the reaction was monitored by TLC (hex-
ane/ethyl acetate 1/1 v/v). Upon completion, the reaction
mixture was concentrated under reduced pressure and the
residue was purified by column chromatography (CH2Cl2/
MeOH 97/3) to afford 97 mg (78 %) of tert.-butyl ester
intermediate as a white powder. TLC: (EtOAc/hexane
1/1): Rf = 0.45.
1H-NMR (600 MHz, CDCl3) δ: 1.39 (s, 9H),
1.41–1.46 (m, 19H), 1.51–1.63 (m, 2H), 1.64–1.71 (m, 1H),
1.73–1.80 (m, 1H), 1.80–1.86 (m, 1H), 1.98–2.08 (m, 1H),
2.25–2.39 (m, 2H), 3.33–3.42 (m, 1H), 3.50–3.59 (m, 1H),
3.69–3.77 (m, 1H), 4.45–4.24 (m, 2H), 5.59 (t, 1H, J =
9.5 Hz), 5.88 (t, 1H, J = 9.8 Hz), 7.00 (d, 1H, J = 8.1Hz),
7.81–7.90 (m, 1H), 8.41 ( t, 1H, J = 7.9 Hz), 8.81 (s, 1H).
13C-NMR (150.9 MHz, CDCl3) δ: 23.36, 27.81, 27.88, 27.95,
28.04, 28.66, 31.51, 32.43, 39.93, 53.12, 53.69, 80.72, 81.64,
82.54, 109.09 (d, J = 37.6 Hz), 128.56 (d, J = 4.3 Hz) 140.96
(d, J = 8.7 Hz), 147.95 (d, J = 13.1 Hz), 157.60, 164.86
164.87 (d, J = 244 Hz), 172.16, 172.31, 173.49. m/z (ESI)
C30H47FN4O8 ([M + H
+]) calcd. 611.3, found 611.3.
Tert.-butyl ester intermediate was treated with 6 mL
of CH2Cl2/TFA (1/1 v/v) for 8 h at 25 °C, concentrated
under reduced pressure, and purified by HPLC. HPLC
purification was performed on a semi-preparative Jupiter
C12 column (100 Å, 10 μm, 250 × 10 mm). The eluting
solvent started with a 10/90 CH3CN/(water 0.5 % TFA)
gradient for 5 min at a flow rate of 2 mL min−1 followed
by a gradient from 10/90 to 70/30, v/v, for 25 min. Com-
pound DCFPyL eluted at 14.5 min, and after solvent re-
moval, 54 mg (67 %) of DCFPyL was isolated as a white
powder. 1H-NMR (400 MHz, D2O) δ: 1.42–1.56 (m, 2H),
1.60–1.73 (m, 2H), 1.73–1.83 (m, 1H), 1.85–1.95 (m, 1H),
1.95–2.05 (m, 1H), 2.13–2.24 (dt, 1H, Jd = 20.6 Hz, Jt =
7.5 Hz), 2.51 (t, 2H, J = 7.2 Hz), 3.43 (t, 2H, 6.5 Hz), 4.25
(ddd, 2H, J = 9.4 Hz, J = 5.1 Hz, J = 9.2 Hz), 7.23 (d, 1H,
J = 8.2 Hz), 8.31 (dt, 1H Jt = 8.2 Hz, Jd = 2.2 Hz), 8.57 (d,
1H, J = 2.2 Hz).13C-NMR δ (125.7 MHz, D2O): 23.26,
27.11, 28.56, 31.00, 31.55, 40.68, 53.51, 54.07, 109.05 (d,
J = 37.8 Hz), 128.47 (d, J = 4.4 Hz) 140.87 (d, J = 8.1 Hz),
147.98 (d, J = 12.9 Hz), 160.26, 164.62 (d, J = 240.1 Hz),
168.16, 177.12, 178.05, 178.19. m/z (HRMS) C18H22FN4O8
([M −H+]) calcd. 441.1427, found 441.1430.
6-Trimethylammonium-nicotinic acid 2,3,5,6-
tetrafluorophenyl ester triflate salt 8 (adapted from
reference [21])
One gram (6.34 mmol) of 6-chloronicotinic acid 7; 1.1 g
(6.5 mmol) of 2,3,5,6 tetrafluorophenol; and 1.31 g
(6.34 mmol) of N,N′-dicyclohexylcarbodiimide (DCC) were
stirred in dioxane (40 mL) for 5 h at 25 °C. Progress of
the reaction was monitored by TLC (EtOAc/hexane 4/1).
Upon completion, the reaction mixture was filtered and
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concentrated under reduced pressure and the residue was
purified by recrystallization in hot hexane to afford 1.35 g
(70 %) of the 6-chloronicotinic acid active ester inter-
mediate as a white powder [18]. TLC: (EtOAc/hexane
4/1): Rf = 0.28.
1H-NMR (600 MHz, CDCl3) δ 7.11 (tt, 1H,
J = 7.1 Hz, J = 9.9 Hz), 7.57 (d, 1H, J = 8.3 Hz), 8.43 (dd,
1H, J = 8.3 Hz, J = 2.7 Hz), 9.21 (d, 1H, J = 2.7Hz). m/z
(ESI) C12H4ClF4NO2 ([M +H
+]) calcd. 305.0, found 304.9.
6-Chloronicotinic acid active ester intermediate (130 mg)
[18] was dissolved in 3 mL of a 1 M Me3N solution in THF
and stirred 2 h at 25 °C. After 5 min, a white precipitate
was formed. After completion of the reaction, the precipi-
tate was collected by filtration and washed with diethyl
ether and cold CH2Cl2. The obtained white powder was
suspended in 5 mL of CH2Cl2 containing 2 % TMSOTf and
sonicated for 10 min. The reaction mixture was concen-
trated under reduced pressure and washed with diethyl
ether to afford 140 mg (68 % over two steps) of a gray
powder after drying. 1H-NMR (600 MHz, CD3CN) δ
7.43 (tt, 1H, J = 7.4 Hz, J = 10.5 Hz), 8.07 (dd, 1H, J =
8.6 Hz, J = 0.8 Hz), 8.85 (dd, 1H, J = 8.6 Hz, J = 2.3 Hz), 9.34
(dd, 1H, J = 2.3 Hz, J = 0.8 Hz). m/z (ESI) C15H13F4N2O2




To a solution of 80 mg (164 μmol) of compound 5 in
CH2Cl2 (4 mL) was added compound 8 (100 mg, 209 μmol)
and 100 μL of DIPEA (572 μmol). The reaction was stirred
for 2 h at 25 °C and then concentrated under reduced
pressure.
Progress of the reaction was monitored by TLC:
(CH2Cl2/MeOH 4/1): Rf = 0.26. HPLC purification was
performed on a semi-preparative Jupiter C12 column
(100 Å, 10 μm, 250 × 10 mm). The eluting solvent started
with a gradient from 5/95 to 70/30 acetonitrile/(water 0.5 %
TFA) for 20 min at a flow rate of 2 mL min−1. Then the
eluent was kept at 70/30 acetonitrile/(water 0.5 % TFA) for
10 min to elute the desired compound at 25.8 min. After
removal of the solvent under reduced pressure gave 96 mg
(77 %) of desired compound 9 as a white powder. 1H-NMR
(600 MHz, D2O) δ: 1.32 (s, 9H), 1.34 (s, 9H), 1.35(s, 9H),
1.35–1.39 (m, 2H) 1.55–1.66 (m, 3H), 1.70–1.82 (m, 2H),
1.95–2.03 (m, 1H), 2.30 (M, 2H), 3.36 (t, 2H, J = 6.8 Hz),
3.57 (s, 9H), 4.02 (ddd, 2H, J = 9.5 Hz, J = 8.7 Hz, J =
5.1 Hz), 7.94 (d, 1H, J = 8.8 Hz), 8.35 (dd, 1H Jt = 8.8 Hz, Jd
= 2.3 Hz), 8.57 (d, 1H, J = 2.3 Hz). 13C-NMR (125.7 MHz,
D2O) δ: 23.35, 27.63, 28.19, 28.20, 28.31, 28.78, 31.92,
32.58, 40.80, 54.34, 54.99, 56.06, 83.47, 84.18, 84.36, 115.48,
118.47, 133.37, 141.14, 148.90, 160.16, 167.46, 174.55,
175.14, 175.33. m/z (HRMS) C33H56NO8 ([M
+]) calcd.
650.4123, found 650.4116. Mp = 56 °C.
Radiosynthesis and quality control of [18F]DCFPyL
Radiosynthesis of [18F]DCFPyL was performed on a
GE TRACERlabTM FX (GE Healthcare, Mississauga,
ON, Canada). The synthesis module was modified in
terms of program and hardware (see Fig. 3). The synthesis
unit was installed and operated in a shielded hot cell.
Analytical HPLC was carried out using a Gilson HPLC
(Mandel Scientific Company Inc.; Guelph, Ontario,
Canada) by injection of HPLC-purified [18F]DCFPyL
onto a Phenomenex Nucleosil Luna C18 column (10 μm,
250 × 10 mm) and elution with 20 % CH3CN/0.2 % TFA
for 5 min at 2 mL min−1, followed by gradient elution
from 20 % to 38 % CH3CN for 5 min and from 38 % to
70 % CH3CN for 15 min with isocratic elution at 70 %
CH3CN for 15 min. Radio-TLC analysis on silica gel plates
gave a Rf value of 0.6 in 95 % CH3CN/H2O (Additional file
1: Figure S4).
Automated synthesis of [18F]DCFPyL
Radiosynthesis of [18F]DCFPyL was performed on a GE
TRACERlabTM FX (GE Healthcare, Mississauga, ON,
Canada). The synthesis module was modified in terms of
program and hardware (Fig. 3). The synthesis unit was
installed and operated in a shielded hot cell.
In vivo tumor models
All animal experiments were carried out in accordance
with the guidelines of the Canadian Council on Animal
Care (CCAC) and approved by the local animal care com-
mittee (Cross Cancer Institute, University of Alberta).
PET imaging experiments were carried out in LNCaP
and PC3 tumor-bearing Balb/c nude mice (Charles River
Laboratories, Quebec, Canada). Male Balb/c nude mice
were housed under standard conditions with free access
to standard food and tap water. LNCaP and PC3 cells
(5 × 106 cells in 100 μL of PBS) were injected into the
upper left flank of the mice (20–24 g). Before injecting
LNCaP cells, the mice received a 1.0-mg/pellet containing
testosterone in a 60-day release preparation (Innovative
Research of America, Sarasota, FL, USA).
The pellet was implanted subcutaneously into the
upper right flank in order to provide a constant level of
testosterone needed by the androgen receptor positive
LNCaP cells. Tumors reached sizes of approximately
1 cm3 which were suitable for all in vivo experiments.
Radiometabolite analysis
Normal BALB/c mice were injected with 10–20 MBq of
[18F]DCFPyL. Venous blood samples were collected at 5,
15, 30, and 60 min p.i. via the mouse tail vein and further
processed. Blood cells were separated by centrifugation
(13,000 rpm × 5 min). Precipitation of proteins in the
supernatant was achieved by the addition of 2 volume
parts of MeOH, and the samples were centrifuged again
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(13,000 rpm × 5 min). Fractions of blood cells, proteins,
and plasma were measured in a Wizard gamma counter
to determine radioactivity per sample. The clear plasma
supernatant was injected onto a Shimadzu HPLC system.
The samples were analyzed using a Phenomenex Luna
10u C18 [2] 100 A, 250 × 4.6 mm column at a constant
flow rate of 1 mL min−1 and the following gradient with
water/0.2 % TFA as solvent A and CH3CN as solvent B:
0–7.5 min 20 % B, 7.5–15 min gradient to 90 % B, 15–
20 min 90 % B.
Dynamic PET imaging
General anesthesia of tumor-bearing mice was induced
with inhalation of isoflurane in 40 % oxygen/60 % nitro-
gen (gas flow = 1 mL min−1), and the mice were subse-
quently fixed in prone position. The body temperature
was kept constant at 37 °C for the entire experiment.
The mice were positioned in a prone position into the
center of the field of view. A transmission scan for at-
tenuation correction was not acquired. The mice were
injected with 2–10 MBq of [18F]DCFPyL (60–150 ng) in
100–200 μL of isotonic NaCl solution (0.9 %) through a
tail vein catheter. For blocking studies, the animals were
pre-dosed with 300 μg of DCFPyL in 50 μL saline about
10 min prior to radiotracer injection. Data acquisition
was performed over 60 min in a 3D list mode. The dy-
namic list mode data were sorted into sinograms with 53
time frames (10 × 2, 8 × 5, 6 × 10, 6 × 20, 8 × 60, 10 × 120,
5 × 300 s). The frames were reconstructed using max-
imum a posteriori (MAP) as reconstruction mode. The
pixel size was 0.085 × 0.085 × 0.121 mm3 (256 × 256 ×
63), and the resolution in the center of the field of view
was 1.8 mm. No correction for partial volume effects
was applied. The image files were processed using the
ROVER v 2.0.51 software (ABX GmbH, Radeberg,
Germany). Masks defining 3D regions of interest (ROI)
were set and the ROIs were defined by thresholding.
Mean standardized uptake values [SUV]mean = (activity/
mL tissue)/(injected activity/body weight), mL/g, were cal-
culated for each ROI. Time-activity curves (TACs) were
generated for the dynamic scans only. All semi-quantified
PET data are presented as means ± SEM. Statistical differ-
ence for the blocking study was tested by unpaired Stu-
dent’s t test and was considered significant for P < 0.05.
Internalization experiments
105 LNCaP or PC3 cells were seeded in poly-D-lysine-
coated 12-well plates 24–48 h before the assay so that
cells could reach 95 % confluency. The medium was re-
moved 1 h before the assay, and the cells were rinsed
twice with PBS. After the addition of Krebs buffer
(1 mL) to each well, the cells were incubated at 37 °C.
Krebs buffer was aspirated, and the cells were incubated
with 300 μL of [18F]DCFPyL in 0.9 % NaCl (0.1 MBq )
for 60 min at 37 °C. Cellular uptake was stopped by re-
moving incubation media from the cells and washing the
wells twice with ice-cold PBS buffer (1 mL). Surface-
bound radioactivity was removed from the cells through
incubating the cells twice with 0.5 mL glycine-HCl in
PBS (50 mM, pH 2.5) for 5 min at 37 °C. Cells were
washed again with ice-cold PBS before the addition of
radio-immunoprecipitation assay (RIPA) buffer (400 μL)
to lyse the cells. Cells were returned into the incubator
for 10 min, and cell lysates were collected for counting.
Radioactivity of surface-bound and internalized fraction
was measured in a WIZARD2 Automatic gamma coun-
ter (Perkin Elmer, Waltham, MA, USA). Total protein
concentration in the samples was determined by the
bicinchoninic acid method (BCA; Pierce, Thermo Scien-
tific 23227) using bovine serum albumin (800, 600, 400,
300, 200, 100, 50 μg/mL, blank) as protein standard.
Data are expressed as percent of total uptake per 1 mg
protein (% of total uptake/mg protein).
Tracer kinetic analysis
Tracer kinetic analysis was performed using a two-tissue
compartmental model using dynamically acquired PET
imaging data. Full details on tracer kinetic analysis are
given in the Additional file 1.
Results
Chemistry and radiochemistry
Synthesis of lysine-urea-glutamate peptidomimetics as
highly potent PSMA-binding motifs is given in Fig. 2.
Compounds 4, 5, and DCFPyL were previously described
in the literature [15, 16]. Herein, we present an improved
synthesis route [15, 16].
Synthesis commenced with the activation of tert-butyl
ester protected amino acid H-Glu(OtBu)-OtBu.HCl 1
with N,N′-disuccinimidyl carbonate to give correspond-
ing NHS ester (S)-(1,5-di-tert-butoxy-1,5-dioxopentan-2-
yl)carbamic acid 2 in 87 % yield. Coupling of active ester
2 with μ-benzyloxycarbonyl-L-lysine tert-butyl ester (H-
Lys(Z)-OtBu.HCl) 3 afforded 2-(3-{1-tert-butylcarboxy-
late-5-[(carboxybenzyl)-amino]-pentyl}-ureido)-di-tert-
butyl pentanedioate 4 in 92 % yield. Removal of the Z
protecting group in compound 4 using hydrogenation
on Pd/C gave 2-{3-[1-tert-butylcarboxylate-(5-aminopen-
tyl)-ureido}-di-tert-butyl pentanedioate 5 in high chemical
yields of 95 %.
The free amine in 5 was acylated with 6-fluoronicotinic
acid 6 in the presence of HBTU followed by acidic cleavage
of tert-butyl ester groups using trifluoroacetic acid (TFA) to
give reference compound 2-(3-{1-carboxy-5-[(6-fluoropyri-
dine-3-carbonyl)-amino]-pentyl}-ureido)-pentanedioic acid
(DCFPyL) in 53 %. The total yield for the four step synthe-
sis of DCFPyL was 40 %.
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Trimethylammonium salt 9, which was the precursor
for direct radiofluorination, was prepared by acylation
reaction of compound 5 with active ester N,N,N-tri-
methyl-5-((2,3,5,6-tetrafluorophenoxy)carbonyl)-pyridin-
2-aminium triflate 8. Active ester 8 was prepared with
slight modifications based on a published procedure [21]
in 68 % yield in two steps starting from 6-chloronicotinic
6 acid. Activation with 2,3,5,6-tetrafluorophenol gave
compound 7 which was treated with trimethylamine
followed by TMSOTf to afford compound 8. Compound 9
was obtained through reaction of compound 5 with active
ester 8 in 77 % yield after purification by HPLC.
Automated radiosynthesis of [18F]DCFPyL was per-
formed on a GE TRACERlabTM FXFN automated synthesis
unit (ASU) equipped with an integrated HPLC system
using a Luna semi-prep HPLC column (Fig. 3).
The overall radiosynthesis of [18F]DCFPyL is displayed
in Fig. 4, and the optimized HPLC purification is given in
the supplementary materials (Additional file 1: Figure S3).
In the first reaction step (R1), cyclotron-produced no-
carrier added (n.c.a.) [18F]fluoride was captured from
[18O]H2O target solution onto a Chromafix cartridge. A
solution (0.6 mL) containing Bu4N
+-HCO3
− (0.3 mL,
0.075 M) and CH3CN (0.3 mL) was used to elute n.c.a.
[18F]fluoride from the resin into the reactor. The aqueous
[18F]fluoride solution was dried azeotropically through
consecutive addition and removal of anhydrous CH3CN.
The first drying cycle was performed at 55 °C for 1 min at
0.1 bar. After the addition of CH3CN (2 mL), solvents
were evaporated at 55 °C for 1 min at 0.1 bar followed by
an evaporation step at 95 °C for 3 min under high vacuum
(0.01 bar). The end of the process yielded activated n.c.a.
[18F]fluoride suitable for subsequent nucleophilic radio-
fluorination. This three-step azeotropic distillation allows
for minimum dispersion of [18F]fluoride on the side of the
reactor vial and concentrates most of the radioactivity at
the bottom of the reactor. This is important for the subse-
quent radiolabeling step which uses only a small volume
of solvent (0.5 mL).
The second reaction (R2) involved combining n.c.a.
[18F]fluoride and 9 to form compound 10 via a nucleo-
philic heteroaromatic substitution reaction. Radiofluori-
nation was carried out with 5 mg of labeling precursor 9
in anhydrous CH3CN (0.5 mL) at 60 °C for 10 min.
Final reaction step (R3) included removal of the tert.-
butyl ester protecting groups in compound 10 via acidic
cleavage using 1.5 mL of HCl (10 N) in 1 mL CH3CN at
40 °C for 5 min to give crude [18F]DCFPyL.
The pH of the crude reaction mixture was adjusted by
the addition of 2 mL of 0.1 M NaOAc (pH 5.8), and the
reaction mixture was transferred into a 5-mL injection
loop and injected onto a Luna C-18 column (10 μm,
250 × 10 mm) for purification employing isocratic elu-
tion with 18 % EtOH containing 0.2 % H3PO4 at a flow
rate of 2 mL min−1. Product peak was collected between
22 and 23 min (Additional file 1: Figure S3). The collected
peak (~2 mL) was transferred, through a sterile filter, into
a sterile vial containing 12 mL of 0.1 M NaOAc (pH 5.8).
The total synthesis time was 55 min, including HPLC
purification. The overall isolated radiochemical yield of
[18F]DCFPyL was 23 ± 5 % (n = 10, decay-corrected).
Quality control of [18F]DCFPyL
Identity of [18F]DCFPyL was confirmed by radio-HPLC
and radio-TLC using co-injection and co-spotting with
reference compound [19F]DCFPyL, respectively. Repre-
sentative HPLC traces are given in Fig. 5a. Quality con-
trol revealed high radiochemical purity of 98 %, and the
Fig. 2 Synthesis of lysine-urea-glutamate peptidomimetics
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specific activity was determined to be 80–100 GBq/μmol
(Fig. 5b, Additional file 1: Figures S5 and S6) starting with
15 to 26 GBq of n.c.a. [18F]fluoride. Radio-TLC analysis on
silica gel plates gave a Rf value of 0.6 in 95 % CH3CN/H2O
(Additional file 1: Figure S4), and the product was stable
(>95 %) in saline of up to 4 h.
Cell-specific internalization experiments
Radiotracer [18F]DCFPyL revealed substantial higher cell
membrane accumulation and internalization in PSMA+
LNCaP cells compared to PSMA− PC3 cells (Fig. 6). After
incubation for 60 min, cellular uptake of [18F]DCFPyL was
stopped and cells were washed with glycine-HCl to re-
move radioactivity bound to the membrane. Internalized
fraction of radioactivity was determined after lysing the
cells with RIPA buffer. After 60 min, radioactivity uptake
in PSMA+ LNCaP cells reached 45.47 ± 1.01 % of total up-
take/mg protein for the membrane-bound fraction and
35.05 ± 0.69 % of total uptake/mg protein for the internal-
ized fraction. This reflects a 44 % fraction of internalized
radioactivity in PSMA+ LNCaP cells after incubation with
radiotracer [18F]DCFPyL for 60 min. In contrast, only
4.30 ± 0.40 % of total uptake/mg protein and 0.76 ± 0.05 %
of total uptake/mg protein were found in the membrane-
bound and internalized fraction, respectively, in the case
of PSMA− PC3 cells.
Dynamic PET imaging experiments
Radiotracer [18F]DCFPyL was injected into PSMA+ LNCaP
and PSMA− PC3 tumor-bearing BALB/c nude mice. As
shown in Fig. 7, high radioactivity uptake and retention was
observed in the PSMA+ LNCaP tumor, whereas only very
Fig. 3 Automated synthesis unit for the radiosynthesis of [18F]DCFPyL
Bouvet et al. EJNMMI Research  (2016) 6:40 Page 8 of 15
Fig. 4 Radiosynthesis of [18F]DCFPyL
Fig. 5 a HPLC traces for confirmation of identity after co-injection of [18F]DCFPyL with reference compound DCFPyL and b quality control of the
final product. Detectors are connected in series
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low uptake and no retention was seen in the PSMA− PC3
tumor. Analyzed TACs describe a continuous increase of
radioactivity accumulation and retention in the PSMA+
LNCaP tumor over 60 min reaching a standardized uptake
value (SUV60min) of 1.1 ± 0.1 (n = 5).
In contrast, PSMA− PC3 tumors showed some radio-
activity uptake during the perfusion phase followed by
rapid washout of radioactivity reaching a SUV of 0.1
(n = 2) at 60 min p.i..
In both prostate cancer models, radioactivity is rapidly
cleared from blood and muscle. Radiotracer [18F]DCFPyL
is eliminated through the kidneys with somewhat more re-
tention of radioactivity in the kidneys in the PC3 model.
Only very little radioactivity is found in all other organs
resulting in a low background signal. Rapid clearance from
blood and muscle tissue led to high tumor-to-blood and
tumor-to-muscle ratios of 8.9 ± 1.9 and 17.0 ± 3.4, respect-
ively, after 60 min p.i. in LNCaP-bearing mice.
Specificity of radiotracer [18F]DCFPyL for PSMA was
demonstrated through blocking experiments in the
LNCaP model. LNCaP PSMA+ model was injected with
300 μg of nonradioactive DCFPyL 5 min prior to the ad-
ministration of radiotracer [18F]DCFPyL. Control and
blocking experiments were carried out in the same ani-
mal on 2 consecutive days.
Acquired PET images confirmed substantial decrease
of radioactivity uptake in the LNCaP tumor, which was
statistical significant (P = 0.0069). Radioactivity uptake was
reduced by 80 % after 60 min p.i. upon pretreatment with
DCFPyL (SUV60min control: 1.1 ± 0.1, n = 5; SUV60min
blocked: 0.2 ± 0.05, n = 4). Uptake in the kidneys was also
reduced (Fig. 8).
In vivo metabolic stability of [18F]DCFPyL
In vivo metabolic stability of [18F]DCFPyL was studied
by analyzing murine blood samples at different time
points and urine after 60 p.i. using radio-HPLC. Figure 9
summarizes the results reflecting the distribution pattern
of radioactivity in blood cells, plasma proteins, and plasma
over time. The overall distribution of radioactivity in the
different blood compartments remained mainly unchanged
over time, suggesting rapid equilibration of radioactivity
distribution between analyzed blood compartments. The
majority of radioactivity is found in the plasma fraction in-
dicating high bioavailability of radiotracer [18F]DCFPyL.
Radio-HPLC analysis of the plasma samples at different
time points confirmed very high metabolic stability of the
radiotracer.
High stability of [18F]DCFPyL was also found in urine
samples after 60 min p.i. In all cases, no radiometabolites
were detected in plasma and urine samples over the studied















Fig. 6 Cell-specific internalization experiments of [18F]DCFPyL in
PSMA+ LNCaP and PSMA− PC3 cells 60 min after incubation with
the radiotracer at 37 °C
Fig. 7 PET images of [18F]DCFPyL after 60 min p.i. into LNCaP (left) and PC3 (right) tumor-bearing BALB/c nude mice. Middle: Time-activity curves
for radioactivity uptake in LNCaP and PC3 tumor
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Tracer kinetic analysis
Cellular uptake of [18F]DCFPyL is presumed to follow a
two-step process, consisting of first binding to PSMA on
the cell membrane and then transport of the [18F]DCFPyL-
PSMA complex into the cytoplasm. We have therefore
modeled the tracer kinetics of [18F]DCFPyL using a revers-
ible two-tissue compartmental model. Tracer kinetic
analysis was carried out with PET imaging data acquired
dynamically from PSMA+ LNCaP and PSMA− PC3
tumor-bearing mice (see Fig. 7). Four kinetic parameters
(K1, k2, k3, k4) describing the flow of the radiotracer from
the blood to the tissue (K1) and from the tissue into the
blood (k2), binding of the radiotracer to the tissue (k3) and
dissociation from the tissue (k4), were calculated.
The analysis was performed by fitting the measured
TACs with a two-exponential model of the general form
as described, e.g., by van den Hoff (Additional file 1:
Figure S2) [22]. Results for the four kinetic parameters
are given in Fig. 10.
The net delivery (K1/k2) of the radiotracer to the tissue
was comparable for LNCaP (K1/k2 = 0.62) and PC3 (K1/
k2 = 0.49) tumors. However, radiotracer [
18F]DCFPyL
accumulated significantly (10.25 times) more in PSMA+
LNCaP tumors compared to PSMA− PC3 tumors (k3
(LNCaP) 0.082 vs. k3 (PC3) 0.008). The coefficient k3/
(k3 + k2) describes the fraction of radiotracer entering
the second compartment (i.e., being bound as opposed
to being released back into the blood pool): the value
for LNCaP (0.314) dominates that of PC3 (0.058) by
more than a factor 5. Significant differences were also
found in the dissociation rate (k4) of the radiotracer
from the tumor (k4 (LNCaP) 0.004 vs. k4 (PC3) 0.061).
Overall, this led to high retention of the radiotracer in
LNCaP tumors (k3/k4 = 20.5) and negligible retention
in PC3 tumors (k3/k4 = 0.13).
Discussion
The present study described the automated radiosynthesis
and preclinical validation of (S)-2-[3-((S)-1-carboxy-5-[3-(6-
fluoropyridine)carbonyl)amino)pentyl)ureido]-pentanedioic
acid ([18F]DCFPyL) as a radiotracer for molecular imaging
of prostate-specific membrane antigen (PSMA) in prostate
cancer. We performed the radiosynthesis of [18F]DCFPyL
employing direct nucleophilic heteroaromatic substitution
as novel synthesis route in an ASU. The radiopharmacolo-
gical evaluation of [18F]DCFPyL included dynamic PET im-
aging, metabolic profiling, and tracer kinetic analysis.
The following important results emerged from this
study: [1] radiotracer [18F]DCFPyL can be prepared in
good radiochemical yields suitable for clinical applica-
tions via a direct radiofluorination synthesis route in an
automated GE TRACERlabTM FXFN synthesis unit; [2]
radiopharmacological profile of [18F]DCFPyL prepared
in an ASU via direct radiofluorination agrees as expected
with previously published work such as high specific
uptake and retention in PSMA+ tumors, very high
metabolic stability, and high bioavailability in vivo.
The first part of this study was focused on the devel-
opment of a novel and automated radiosynthesis of
[18F]DCFPyL using a direct radiolabeling approach with
cyclotron-produced n.c.a. [18F]fluoride. Radiochemistry
with prosthetic groups for 18F labeling represents a special
challenge for robust and reliable radiotracer synthesis, es-
pecially when automated processes according to GMP
guidelines for clinical applications are required. Literature
reports on syntheses of 18F-labeled small-molecule PSMA
Fig. 8 PET images of [18F]DCFPyL after 60 min p.i. into a LNCaP tumor-bearing BALB/c nude mouse. Left: control; Middle: time-activity curves for
uptake and blocking in LNCaP tumors in the absence and presence of nonradioactive DCFPyL; Right: blocked
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inhibitors like [18F]DCFPyL mainly involved multiple step
reactions using manual synthesis procedures which pro-
vided modest to good radiochemical yields [15, 17–19].
Reported decay-corrected radiochemical yields for the
preparation of [18F]DCFPyL using prosthetic group 2,3,5,6-
tetrafluorophenyl-6-[18F]fluoronicotinate ([18F]FPy-TFP)
vary greatly from 5 to 53 % [12, 13, 15]. Low radiochemical
yields (decay-corrected) in the range of 5–12 % are reported
for [18F]DCFPyL when the radiotracer was produced for
clinical trials [12, 13]. In one case, the radiosynthesis was
carried out in a modified dual-run FDG synthesis module
[13]. Higher decay-corrected radiochemical yields of
36–53 % were reported for the original manual synthesis
of [18F]DCFPyL when modest amounts (1.6–2.2 GBq) of
[18F]fluoride were used [15]. Various literature reports
documented excellent radiochemical yields for direct
nucleophilic heteroaromatic substitution reactions
with n.c.a. [18F]fluoride at the ortho-position to prepare
various 2-[18F]fluoropyridines, including the prosthetic
group [18F]FPy-TFP, under mild conditions [21]. Recent
Fig. 9 Distribution of [18F]DCFPyL in the blood (top) revealing only minimal binding to plasma proteins and therefore good bioavailability and
evaluation of the metabolic stability of [18F]DCFPyL (bottom) following injection in BALB/c mice (n = 3)
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applications and advantages of this methodology for the
design and synthesis of numerous 18F-labeled radiotracers
have extensively been reviewed [23]. Building on this
work, we envisaged a direct radiofluorination synthesis
route based on 2-[18F]fluoropyridine chemistry for the
preparation of [18F]DCFPyL using the trimethylammo-
nium salt 9 as the labeling precursor. Attempts to prepare
[18F]DCFPyL in satisfying radiochemical yields from re-
lated 6-chloronicotinic acid compound were not success-
ful (data not shown).
The use of trimethylammonium salt 9 as labeling pre-
cursor offers several advantages. Notably as a solid, com-
pound 9 allows for convenient handling and storage.
Compound 9 was stored at 4 °C without significant de-
composition for at least 3 months. Moreover, excellent
leaving group properties of the Me3N group in hetero-
aromatic nucleophilic substitution reactions with n.c.a.
[18F]fluoride at the ortho-position of various pyridines
enables radiosynthesis under mild reaction conditions
compatible with technology and equipment of ASU like
the GE TRACERlabTM FXFN synthesis module.
Automated radiosynthesis of [18F]DCFPyL was accom-
plished in three reaction steps using a one reactor set-up in-
volving drying and activation of cyclotron-produced n.c.a.
[18F]fluoride (R1), incorporation of activated [18F]fluoride
into compound 10 via nucleophilic heteroaromatic substi-
tution (R2), and removal of the tert-butyl protecting groups
through treatment with HCl and subsequent HPLC
purification to give final product [18F]DCFPyL (R3).
The fully automated synthesis provided [18F]DCFPyL in
decay-corrected radiochemical yields of 23 ± 5 % (n = 10)
within 55 min, including final HPLC purification. In a typ-
ical synthesis, 3 GBq of [18F]DCFPyL ready for injection
was obtained starting from 20 GBq of n.c.a. [18F]fluoride.
This is sufficient for several patient doses assuming a sin-
gle patient dose of 300–400 MBq of [18F]DCFPyL. The ob-
tained good and highly reproducible radiochemical yield
of 23 ± 5 % clearly demonstrates the favorable features of
the direct radiofluorination synthesis route compared to
the existing method [12, 13, 15] and should help ensure
the availability of the agent. The specific activity was deter-
mined to be 80–100 GBq/μM. Radiotracer [18F]DCFPyL
passed standard quality control test, making module-
prepared [18F]DCFPyL suitable for human studies.
The second part of this study dealt with the evaluation
of module-prepared [18F]DCFPyL in preclinical prostate
cancer models to further confirm pharmaceutical quality
and suitability of the radiotracer for PET imaging of
PSMA in vivo.
Dynamic PET imaging of [18F]DCFPyL has not yet
been reported using PSMA+ LNCaP and PSMA− PC3
tumors. Previously reported studies were using PSMA+
PC3-PIP and PSMA− PC3-flu xenografts [15].
Prostate cancer cell lines LNCaP and PC3 have well-
characterized PSMA expression levels to evaluate PSMA
radiotracers and are therefore suitable for validation of
[18F]DCFPyL prepared from the new method in com-
parison with the original method [15, 17, 18].
As shown in Fig. 6, radiotracer [18F]DCFPyL showed
high uptake in PSMA+ LNCaP tumors with favorable
clearance pattern from blood and muscles. The high up-
take and retention of radioactivity in PSMA+ LNCaP tu-
mors correlates with the reported high inhibitory
potency of [18F]DCFPyL (Ki = 1.1 nM) towards PSMA
[15]. The fast clearance of the radiotracer from the blood,
muscle, and most tissues and organs is in agreement with
the hydrophilic nature of compound [18F]DCFPyL as typ-
ical for peptidomimetic PSMA inhibitors. Uptake of
[18F]DCFPyL in PSMA+ LNCaP tumors (SUV60min = 1.1)
was about 11 times higher compared to PSMA− PC3 tu-
mors (SUV60min = 0.1). After 60 min p.i., only some radio-
activity was also found in the kidney with only very
minimal background radioactivity in the liver. Most of the
injected radioactivity was accumulated in the bladder after
60 min p.i..
This biodistribution profile is consistent with previously
reported studies using [18F]DCFPyL for PET imaging of
PSMA in other prostate cancer models [15]. As expected
for PSMA− PC3 tumors, only very little radioactivity was
found in the tumor at 60 min p.i.. The highest levels of
radioactivity in the PC3 model were also observed in the
kidneys and bladder (Fig. 6).
Renal clearance pathway as seen for urea-based pepti-
domimetic PSMA inhibitor [18F]DCFPyL was also re-
ported for 18F-labeled phosphoramidate peptidomimetic
as small-molecule PSMA-imaging agent in LNCaP- and
PC3-bearing mice [18]. Uptake of radiolabeled phos-
phoramidate in PSMA+ LNCaP tumors was about four
times higher compared to the uptake in PC3 tumors as
determined by ex vivo biodistribution studies.
Favorable radiopharmacological profile and specificity
of [18F]DCFPyL for PSMA imaging in vivo was further











Fig. 10 Tracer kinetic analysis of [18F]DCFPyL in PSMA+ LNCaP and
PSMA− PC3 tumor-bearing Balb/c mice
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confirmed by specific blocking studies with nonradioactive
DCFPyL using the same animal on 2 consecutive days.
The observed 80 % reduction of [18F]DCFPyL uptake in
PSMA+ LNCaP tumors upon blocking with DCFPyL is in-
dicative of specific targeting of [18F]DCFPyL to PSMA.
Metabolic profiling of [18F]DCFPyL in mice revealed
low binding of the radiotracer to blood cells and plasma
proteins leading to high bioavailability. Analyzed plasma
samples further confirmed remarkable high metabolic
stability of [18F]DCFPyL. No radiometabolites were de-
tected by radio-HPLC analysis over 60 min p.i. High
metabolic stability was further confirmed by analysis of
urine samples at 60 min p.i., which contained only par-
ent compound [18F]DCFPyL.
In the last part of this study, we applied tracer kinetic
analysis to quantify and compare pharmacokinetics of
[18F]DCFPyL for PSMA imaging in preclinical LNCaP
and PC3 prostate cancer models. Delivery of the radio-
tracer (K1) is dependent on blood flow, and our data in-
dicate that radiotracer delivery was elevated for LNCaP
tumors. However, net delivery as expressed by the K1/k2
ratio was comparable for both tumor models (LNCaP:
0.62; PC3: 0.49).
The observed high uptake and retention of [18F]DCFPyL
in LNCaP tumors was also reflected by the calculated k3
values for both tumors. This was further supported by the
coefficient k3/(k3 + k2), which was five times higher for
LNCaP tumors compared to PC3 tumors.
Kinetic parameter k3 reflects the binding of the radio-
tracer to the tissue, and the k3 value for LNCaP is about
10 times higher than the k3 value for PC3. Tracer bind-
ing is favored in PSMA+ LNCaP tumors, as expressed
by the ratio k3/k4, and is more than 150 times higher
than for PC3 tumors. This led to an 11 times higher up-
take of the radiotracer in LNCaP tumors, based on SUV
values at 60 min p.i.. The high retention of radioactivity
in the LNCaP model can be explained by high affinity
binding of the radiotracer to PSMA and internalization
of the PSMA-ligand complex. This is supported by the
cell-specific internalization experiments in PSMA+ LNCaP
and PSMA− PC3 cells. High retention of radioactivity in
LNCaP tumors and rapid clearance of radioactivity from
most tissues and organs support findings from earlier work
on [18F]DCFPyL as an ideal radiotracer for PSMA imaging
in vivo [15].
Conclusions
We have developed an automated synthesis for radiotracer
[18F]DCFPyL based on a direct radiofluorination synthesis
route. We demonstrated that [18F]DCFPyL can be prepared
in good radiochemical yields and pharmaceutical quality
suitable for clinical applications for PSMA imaging in
humans. The automated synthesis based on direct radio-
fluorination should improve availability of [18F]DCFPyL for
PSMA imaging in humans. Dynamic PET imaging of
[18F]DCFPyL in PSMA+ LNCaP and PSMA− PC3
tumor-bearing mice confirmed the previously reported
data describing high PSMA-mediated tumor uptake and
favorable clearance profile of the radiotracer. Compart-
mental model analysis points to a two-step molecular
trapping process based on PSMA binding and subsequent
internalization leading to retention of radioactivity in
PSMA+ LNCaP tumors. These findings further under-
line the excellent characteristics of [18F]DCFPyL for PET
imaging of PSMA in vivo.
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